Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Jess Amchin"'
Autor:
Maha Ahmad, James Kelly, C. Brendan Montano, Dinesh Kumar, Carlos Perdomo, Manoj Malhotra, Jess Amchin, Margaret Moline
Publikováno v:
Sleep Medicine: X, Vol 7, Iss , Pp 100098- (2024)
Objective: Few clinical studies have assessed real-world abrupt transitioning between insomnia medications. This study assessed strategies for directly transitioning patients from zolpidem tartrate (ZOL) immediate/extended release to the dual orexin
Externí odkaz:
https://doaj.org/article/990b45dcbbf74efabd62d2823908ac0d
Autor:
Manoj Malhotra, Dinesh Kumar, Maha Ahmad, Carlos Perdomo, Jess Amchin, Margaret Moline, Norman Atkins
Publikováno v:
Sleep. 44:A134-A135
Introduction Dosing paradigms for transitioning patients to lemborexant (LEM) from zolpidem (ZOL: immediate [IR] or extended-release [ER]) were examined in E2006-A001-312 (Study 312; NCT04009577), an open-label pilot study. Given insomnia prevalence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ceef6121191a29de4008d6799bac865b
https://doi.org/10.1093/sleep/zsab072.336
https://doi.org/10.1093/sleep/zsab072.336
Autor:
Carlos Perdomo, Jess Amchin, Dinesh Kumar, Manoj Malhotra, Margaret Moline, Russell Rosenberg, Norman Atkins
Publikováno v:
Sleep. 44:A134-A134
Introduction E2006-A001-312 (Study 312; NCT04009577) was an open-label pilot study that examined pre-specified dosing paradigms for transitioning patients from zolpidem (ZOL: immediate [IR] or extended-release [ER]) to the dual orexin receptor antago
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f132d2e7b730e229d78f9df3424f2313
https://doi.org/10.1093/sleep/zsab072.334
https://doi.org/10.1093/sleep/zsab072.334
Autor:
Manoj Malhotra, Carlos Perdomo, Russell Rosenberg, Dinesh Kumar, Jess Amchin, Margaret Moline
Publikováno v:
The American Journal of Geriatric Psychiatry. 29:S123
Introduction Treatment for insomnia often includes prescription medication but some commonly prescribed insomnia drugs, such as the GABA-ergic agonist zolpidem (ZOL), are associated with safety concerns in older adults. Studies examining methods for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53661dfa70cd30c26ae50e4129605556
https://doi.org/10.1016/j.jagp.2021.01.118
https://doi.org/10.1016/j.jagp.2021.01.118
Publikováno v:
Journal of Affective Disorders. 197:51-57
Background Safe/well-tolerated treatments for bipolar I depression remain limited. We assessed safety/tolerability of adjunctive open-label armodafinil, a wakefulness-promoting agent evaluated in 3 acute, controlled efficacy studies with variable eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d50890e79edeedfce2043e72e99ab96
https://doi.org/10.1016/j.jad.2016.02.050
https://doi.org/10.1016/j.jad.2016.02.050
Publikováno v:
Sleep. 43:A183-A183
Introduction Patients who take insomnia medication may change medications for reasons including lack of efficacy, adverse events, and dependence concerns. A pilot study (NCT04009577, E2006-A001-312) assessed a dosing approach for transitioning patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::946688f2dc6681bf6c864c9fd0ec2915
https://doi.org/10.1093/sleep/zsaa056.474
https://doi.org/10.1093/sleep/zsaa056.474
Autor:
Margaret Moline, Carlos Perdomo, Russell Rosenberg, Manoj Malhotra, Jess Amchin, Dinesh Kumar
Publikováno v:
Sleep. 43:A183-A183
Introduction Switching of medications for insomnia occurs often in clinical practice based on a variety of reasons. However, few clinical studies have examined methods for transitioning patients between different insomnia medications. This is especia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50c085b5f5a7c354ac4851026a168293
https://doi.org/10.1093/sleep/zsaa056.475
https://doi.org/10.1093/sleep/zsaa056.475
Publikováno v:
International Journal of Bipolar Disorders
Background Some, but not all, prior investigations suggest armodafinil may have utility as an adjunctive treatment in bipolar I depression. Methods Multicenter, randomized, double-blind study in patients aged 18 to 65 years experiencing a depressive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1efcb1fccc988fc5c607388deb95794a
http://europepmc.org/articles/PMC4556715
http://europepmc.org/articles/PMC4556715
Publikováno v:
The Journal of Clinical Pharmacology. 39:252-259
Venlafaxine is a clinically effective antidepressant. Caffeine is a metabolic probe for the quantitative measurement of CYP1A2 activity in vivo. This open-label study evaluated the effect of steady-state venlafaxine on CYP1A2-dependent metabolism, as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb594354416d2ce4d9f21bcb3f49f3b3
https://doi.org/10.1177/009127009903900308
https://doi.org/10.1177/009127009903900308
Publikováno v:
The Journal of Clinical Pharmacology. 39:297-309
An open-label study evaluated the effect of steady-state venlafaxine on the single-dose pharmacokinetic profile of risperidone, a CYP2D6 substrate; its active metabolite, 9-hydroxyrisperidone; and the total active moiety (risperidone plus 9-hydroxyri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61b4bca8205a39fd58a59958e5249f61
https://doi.org/10.1177/009127009903900314
https://doi.org/10.1177/009127009903900314